Germantown

Futó vizsgálatok

• Toboroz

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· Forrás

• Toboroz

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· 2/3. fázis· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Forrás

• Fut, nem toboroz

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· 3. fázis· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

  NCT04556773· 1. fázis· Forrás

• Fut, nem toboroz

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Amiloidózis2 toboroz
• Petefészekrák1 toboroz
• Szívelégtelenség1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· Forrás

• Lezárult

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· 3. fázis· Forrás